Company intelligence / Profile preview

Marchwood

Houston, Texas, United Statesmarchwoodmusic.com ↗

Ownership: Private
Development stage: Other

Overview

March Biosciences' lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials for refractory T-cell lymphoma and leukemia. Early clinical data show promising efficacy and safety. A Phase 2 trial is expected to begin soon, supported by recent Series A financing.

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyCell therapyAutologous chimeric antigen receptor T-cell (CAR-T) therapy
Industry: Biotech

Partnerships

Mission BioCapital (major investor with board representation)4BIO Capital (major investor with board representation)Center for Cell and Gene Therapy at Baylor College of MedicineHouston Methodist HospitalTexas Children's Hospital

Beyond the preview

Go deeper on Marchwood.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marchwood.

Explore the full profile